IL-19 derived from BC cells provided a microenvironment for tumor growth stimulating the expression of MMP-2 and MMP-9, enzymes involved in tumor angiogenesis [49], while IL-22 had corresponding impact by increasing the expression of angiogenic factor, VEGF, through STAT3 activation in human PC cells, an effect reverted by using a Jak-STAT signaling inhibitor, AG490 [95]. The gene discussed is IL22; the disease is breast cancer.